P. B. Chapman, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 2011.

A. V. Hernandez, Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?, Am Heart J, vol.151, pp.257-64, 2006.

G. Guyatt, P. C. Wyer, and J. Ioannidis, User's guide to the medical literature: a manual for evidence-based clinical practice, pp.571-83, 2008.

X. Sun, The influence of study characteristics on reporting of subgroup analyses in randomized controlled trials: systematic review, BMJ, vol.342, p.1569, 2011.

X. Sun, Credibility of claims of subgroup effects in randomised controlled trials: systematic review, BMJ, vol.344, 2012.

A. Heiat, C. P. Gross, and H. M. Krumholz, Representation of the elderly, women, and minorities in heart failure clinical trials, Arch Intern Med, vol.162, issue.15, pp.1682-1690, 2002.

D. N. Kyriacou and R. J. Lewis, Confounding by indication in clinical research, JAMA, vol.316, issue.17, pp.1818-1827, 2016.

R. Varadhan, A framework for the analysis of heterogeneity of treatment effect in patient-centered outcomes research, J Clin Epidemiol, vol.66, issue.8, pp.818-843, 2013.

S. J. Pocock, M. D. Hughes, and R. J. Lee, Statistical problems in the reporting of clinical trials. A survey of three medical journals, N Engl J Med, vol.317, pp.426-458, 1987.

, The BMJ: leading general medical journal, The JAMA Network | Home of JAMA and the Specialty Journals of the American Medical Association

, The New England Journal of Medicine: Research & Review Articles

, PLOS Medicine: A Peer-Reviewed Open-Access Journal

S. F. Assmann, Subgroup analysis and other (mis)uses of baseline data in clinical trials, Lancet, vol.355, pp.1064-1073, 2000.

P. M. Rothwell, Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation, Lancet, vol.365, issue.9454, pp.176-86, 2005.

R. Wang, Statistics in medicine reporting of subgroup analyses in clinical trials, N Engl J Med, vol.357, pp.2189-94, 2007.

A. Liberati, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration, J Clin Epidemiol, vol.62, issue.10, pp.1-34, 2009.

N. Gabler, Dealing with heterogeneity of treatment effects: is the literature up to the challenge?, Trials, vol.10, p.43, 2009.

R. Varadhan and . Hopkins, Estimation and reporting of heterogeneity of treatment effects. Developing an observational CER protocol: a user's guide, Chapter 3

S. Yusuf and J. Wittes, Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials, JAMA, vol.266, pp.93-101, 1991.

C. I. Alatorre, A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas. 2011 Blackwell publishing ltd, Int J Clin Pract, vol.65, issue.8, pp.831-878, 2011.

J. F. Burke, Three simple rules to ensure reasonably credible subgroup analyses, BMJ, vol.351, p.5651, 2015.

D. G. Altman, Better reporting of randomized controlled trials: the CONSORT statement, BMJ, vol.313, issue.7057, pp.570-571, 1996.

V. Elm and E. , The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies, PLoS Med, vol.4, issue.10, 2007.

J. A. Rassen, Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses, Pharmacoepidemiol Drug Saf, vol.21, issue.7, pp.697-709, 2011.

R. H. Perlis, Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry, Am J Psychiatry, vol.162, pp.1957-60, 2005.

, Abridged index medicus (aim or "core clinical") journal titles, 2015.

I. Boutron, Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes, JAMA, vol.303, pp.2058-64, 2010.

K. J. Rothman, S. Greenland, and A. M. Walker, Concepts of interaction, Am J Epidemiol, vol.112, pp.467-70, 1980.

H. C. Sox, M. Helfand, J. Grimshaw, K. Dickersin, D. Tovey et al., Comparative effectiveness research: challenges for medical journals, Am J Manag Care, vol.16, issue.5, pp.131-134, 2010.

S. T. Brookes, Subgroup analyses in randomized trials: risks of subgroupspecific analyses; power and sample size for the interaction test, J Clin Epidemiol, vol.57, pp.229-265, 2004.

D. B. Rubin, For objective causal inference, design trumps analysis, Ann Appl Stat, vol.2, issue.3, pp.808-848, 2008.

. Ga-wells, D. Shea, J. O'connell, . Peterson, M. Welch et al., The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses